# A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

> **NCT04575467** · PHASE2 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514

## Key facts

- **NCT ID:** NCT04575467
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-12-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04575467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04575467, "A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04575467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*